TITLE

Formulation, antileukemia mechanism, pharmacokinetics, and biodistribution of a novel liposomal emodin

AUTHOR(S)
Tiechuang Wang; Xiaodong Yin; Yaping Lu; Weiguang Shan; Subin Xiong
PUB. DATE
January 2012
SOURCE
International Journal of Nanomedicine;2012, Vol. 7, p2325
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
82508974

 

Related Articles

  • Preparation, Pharmacokinetics, Biodistribution, Antitumor Efficacy and Safety of Lx2-32c-Containing Liposome. Wang, Hongbo; Zhang, Jianqiao; Lv, Guangyao; Ma, Jinbo; Ma, Pengkai; Du, Guangying; Wang, Zongliang; Tian, Jingwei; Fang, Weishuo; Fu, Fenghua // PLoS ONE;Dec2014, Vol. 9 Issue 12, p1 

    Lx2-32c is a novel taxane that has been demonstrated to have robust antitumor activity against different types of tumors including several paclitaxel-resistant neoplasms. Since the delivery vehicles for taxane, which include cremophor EL, are all associated with severe toxic effects,...

  • Application of Pharmacokinetic and Pharmacodynamic Analysis to the Development of Liposomal Formulations for Oncology. Ait-Oudhia, Sihem; Mager, Donald E.; Straubinger, Robert M. // Pharmaceutics;Mar2014, Vol. 6 Issue 1, p137 

    Liposomal formulations of anticancer agents have been developed to prolong drug circulating lifetime, enhance anti-tumor efficacy by increasing tumor drug deposition, and reduce drug toxicity by avoiding critical normal tissues. Despite the clinical approval of numerous liposome-based...

  • In Vivo Pharmacokinetic and Tissue Distribution Studies in Mice of Alternative Formulations for Local and Systemic Delivery of Paclitaxel: Gel, Film, Prodrug, Liposomes and Micelles. Dhanikula, Anand Babu; Singh, D. Renu; Panchagnula, Ramesh // Current Drug Delivery;Mar2005, Vol. 2 Issue 1, p35 

    The aim of this study was to increase the understanding on the pharmacokinetic and tissue distribution of paclitaxel as influenced by formulation approach. For this purpose, various formulations investigated in Swiss mice included liposomes, poloxamer 407 gel and chitosan film for subcutaneous...

  • Liposomal Drug Formulations: Rationale for Development and What We Can Expect for the Future. Allen, T.M. // Drugs;Nov1998, Vol. 56 Issue 5, p747 

    Liposomes are versatile drug carriers which can be used to solve problems of drug solubility, instability and rapid degradation. Both hydrophilic and hydrophobic drugs can be associated with liposomes and special techniques have been developed for the efficient loading of weak acids and weak...

  • Development and Stability Studies of Novel Liposomal Vancomycin Formulations. Muppidi, Krishna; Pumerantz, Andrew S.; Wang, Jeffrey; Betageri, Guru // ISRN Pharmaceutics;2012, p1 

    A promising strategy to improve the therapeutic efficiency of antimicrobial agents is targeted therapy. Although vancomycin has been considered a gold standard for the therapy of MRSA pneumonia, clinical failure rates have also been reported owing to its slow, time-dependent bactericidal...

  • Investigation of intravenous delivery of nanoliposomal topotecan for activity against orthotopic glioblastoma xenografts. Serwer, Laura P.; Noble, Charles O.; Michaud, Karine; Drummond, Daryl C.; Kirpotin, Dmitri B.; Ozawa, Tomoko; Prados, Michael D.; Park, John W.; James, C. David // Neuro-Oncology;Dec2011, Vol. 13 Issue 12, p1288 

    Achieving effective treatment outcomes for patients with glioblastoma (GBM) has been impeded by many obstacles, including the pharmacokinetic limitations of antitumor agents, such as topotecan (TPT). Here, we demonstrate that intravenous administration of a novel nanoliposomal formulation of TPT...

  • Dual Physiologically Based Pharmacokinetic Model of Liposomal and Nonliposomal Amphotericin B Disposition. Kagan, Leonid; Gershkovich, Pavel; Wasan, Kishor; Mager, Donald // Pharmaceutical Research;Jan2014, Vol. 31 Issue 1, p35 

    Purpose: To investigate the biodistribution of amphotericin B (AmB) in mice and rats following administration of liposomal AmB (AmBisome®) using a physiologically-based pharmacokinetic (PBPK) modeling framework and to utilize this approach for predicting AmBisome® pharmacokinetics in human...

  • Liposomes (a Review). Chrai, Suggy S.; Murari, R.; Ahmad, Imran // BioPharm International;Nov2001, Vol. 14 Issue 11, p10 

    Discusses the advantages of liposomal drug delivery systems and their necessity in vivo and clearance from the body. Utilization of liposomal formulations in biopharmaceutical development projects; Methods employed in making liposomal systems for drug delivery; Mechanisms of introducing drugs...

  • Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation. Gershkovich, Pavel; Wasan, Ellen K.; Lin, Molly; Sivak, Olena; Leon, Carlos G.; Clement, John G.; Wasan, Kishor M. // Journal of Antimicrobial Chemotherapy (JAC);Mar2010, Vol. 65 Issue 3, p599 

    A correction to the article "Pharmacokinetics and Biodistribution of Amphotericin B in Rats Following Oral Administration in a Novel Lipid-Based Formation" that was published in a 2009 issue, is presented.

  • Targeting of Liposomes via PSGL1 for Enhanced Tumor Accumulation. Carlisle, Robert; Seymour, Leonard; Coussios, Constantin // Pharmaceutical Research;Feb2013, Vol. 30 Issue 2, p352 

    Purpose: To improve the delivery of liposomes to tumors using P-selectin glycoprotein ligand 1 (PSGL1) mediated binding to selectin molecules, which are upregulated on tumorassociated endothelium. Methods: PSGL1 was orientated and presented on the surface of liposomes to achieve optimal selectin...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics